156. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. doi: 10.1034/j.1600- 0404.2002.1o174.x. PMID: 11939936.
157. Myllylä VV, Kultalahti ER, Haapaniemi H, Leinonen M; FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol. 2001 Jan;8(1):53-60. doi: 10.1046/j.1468-1331.2001.00168.x. PMID: 11509081.
158. Chang Y, Wang LB, Li D, Lei K, Liu SY. Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis. Ann Med. 2017 Aug;49(5):421-434. doi: 10.1080/07853890.2017.1293285. Epub 2017 Mar 15. PMID: 28293967.
159. Mínguez-Mínguez S, Solís-García Del Pozo J, Jordán J. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. Pharmacol Res. 2013 Aug;74:78-86. doi: 10.1016/j.phrs.2013.05.005. Epub 2013 Jun 2. PMID: 23735235.
160. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005 Mar 12- 18;365(9463):947-54. doi: 10.1016/S0140-6736(05)71083-7. PMID: 15766996.
161. Binde CD, Tvete IF, Gåsemyr JI, Natvig B, Klemp M. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol. 2020 Dec;76(12):1731- 1743. doi: 10.1007/s00228-020-02961-6. Epub 2020 Jul 24. PMID: 32710141; PMCID: PMC7661406.
162. Clarke C E, Speller J M, Clarke J A. Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2000;(3):CD002261. doi: 10.1002/14651858.CD002261. PMID: 10908540.
163. Clarke CE, Deane KH. Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2001;(1):CD001516. doi: 10.1002/14651858.CD001516. PMID: 11279718.
164. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa- induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996; 19: 234–245.
165. Lieberman A, Olanow CW, Sethi K, et al. A multicen- ter trial of ropinirole as adjunct treatment for Parkin- son’s disease. Ropinirole Study Group. Neurology 1998; 51: 1057– 1062.
166. Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Mov Disord. 2010 May 15;25(7):927-31. doi: 10.1002/mds.23040. PMID: 20461810.
167. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108–1115
168. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W; Pramipexole ER Studies Group. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011 Aug 23;77(8):767-74. doi: 10.1212/WNL.0b013e31822affdb. Epub 2011 Aug 10. PMID: 21832216.
169. Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord. 2005 May;20(5):602-10. doi: 10.1002/mds.20397. PMID: 15726540.
170. Nomoto M, Mizuno Y, Kondo T, Hasegawa K, Murata M, Takeuchi M, Ikeda J, Tomida T, Hattori N. Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neurol. 2014 Oct;261(10):1887-93. doi: 10.1007/s00415-014-7427-3. Epub 2014 Jul 15. PMID: 25022939.
171. LeWitt PA, Poewe W, Elmer LW, Asgharnejad M, Boroojerdi B, Grieger F, Bauer L. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. Clin Neuropharmacol. 2016 Mar- Apr;39(2):88-93. doi: 10.1097/WNF.0000000000000133. PMID: 26882318; PMCID: PMC4791317.
172. LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007 Apr 17;68(16):1262-7. doi: 10.1212/01.wnl.0000259516.61938.bb. PMID: 17438216.
173. Zhao H, Ning Y, Cooper J, Refoios Camejo R, Ni X, Yi B, Parks D. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis. Adv Ther. 2019 Jun;36(6):1252-1265. doi: 10.1007/s12325-019-00938-1. Epub 2019 Apr 8. PMID: 30963514.
174. Clarke C E, Speller J M, Clarke J A. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2000; (3):CD002259. doi: 10.1002/14651858.CD002259. PMID: 10908539.
175. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007 Jun;6(6):513-20. doi: 10.1016/S1474-4422(07)70108-4. PMID: 17509486.
176. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole- Bromocriptine Study Group. Neurology. 1997 Oct;49(4):1060-5. doi: 10.1212/wnl.49.4.1060. PMID: 9339690.
177. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf. 2010 Feb 1;33(2):147-61. doi: 10.2165/11319860-000000000-00000. PMID: 20082541.
178. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):180-7. doi: 10.1111/j.1468-1331.2012.03822.x. Epub 2012 Jul 31. PMID: 22845710.